Recombinant Rat Pcsk9 protein, His & GST-tagged
Cat.No. : | Pcsk9-1156R |
Product Overview : | Recombinant Rat Pcsk9 aa. (Trp164~Phe428 fused with N-terminal His & GST tag was produced in E. coli cells. |
- Specification
- Gene Information
- Related Products
Description : | A soluble zymogen; involved in hepatic growth and differentiation. |
Source : | E. coli |
Species : | Rat |
Tag : | His & GST |
Form : | Freeze-dried powder |
Molecular Mass : | 58kDa as determined by SDS-PAGE reducing conditions. |
Protein length : | Trp164~Phe428 |
Endotoxin : | <1.0EU per 1µg (determined by the LAL method) |
Purity : | >92% |
Characteristic : | The isoelectric point is 5.9. |
Applications : | SDS-PAGE; WB; ELISA; IP; CoIP; ReporterAssays; Purification; Amine Reactive Labeling. |
Stability : | The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition. |
Storage : | Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months. |
Concentration : | 200μg/mL |
Storage buffer : | 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5% Trehalose and Proclin300. |
Reconstitution : | Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0mg/mL. Do not vortex. |
Gene Name : | Pcsk9 proprotein convertase subtilisin/kexin type 9 [ Rattus norvegicus (Norway rat) ] |
Official Symbol : | Pcsk9 |
Synonyms : | Pcsk9; proprotein convertase subtilisin/kexin type 9; PC9; Narc1; NARC-1; neural apoptosis-regulated convertase 1; proprotein convertase 9; proprotein convertase PC9; subtilisin/kexin-like protease PC9 |
Gene ID : | 298296 |
mRNA Refseq : | NM_199253.2 |
Protein Refseq : | NP_954862.2 |
UniProt ID : | P59996 |
Products Types
◆ Recombinant Protein | ||
PCSK9-3273H | Recombinant Human PCSK9 protein(Met1-Gln692), His-tagged, Biotinylated | +Inquiry |
PCSK9-264H | Recombinant Human PCSK9 Protein, His-tagged(C-ter) | +Inquiry |
PCSK9-410H | Recombinant Human PCSK9 Protein, His-tagged | +Inquiry |
PCSK9-407H | Recombinant Human PCSK9 Protein, His-tagged | +Inquiry |
PCSK9-406C | Recombinant Chinese hamster PCSK9 Protein, His-tagged | +Inquiry |
◆ Lysates | ||
PCSK9-2564MCL | Recombinant Mouse PCSK9 cell lysate | +Inquiry |
PCSK9-2875HCL | Recombinant Human PCSK9 cell lysate | +Inquiry |
PCSK9-2775RCL | Recombinant Rhesus PCSK9 cell lysate | +Inquiry |
◆ Assay kits | ||
Kit-1807 | PCSK9[Biotinylated]-LDLR Binding Assay Kit | +Inquiry |
Kit-1806 | PCSK9(D374T)-LDLR TR-FRET Assay Kit | +Inquiry |
Kit-1808 | PCSK9-LDLR TR-FRET Assay Kit | +Inquiry |
Kit-0666 | PCSK9-LDLR in vitro Binding Assay Kit | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (6)
Ask a questionYes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.
PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.
This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.
Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.
Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.
PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.
Customer Reviews (3)
Write a reviewIn immunological experiments, it was found that it had good antigenicity and could induce target immune responses.
It promoted cell growth and proliferation.
High catalytic efficiency.
Ask a Question for All Pcsk9 Products
Required fields are marked with *
My Review for All Pcsk9 Products
Required fields are marked with *
Inquiry Basket